Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib PK in Advanced Cancer with Hepatic Impairment
NCT03726333Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Jan 2020
- Primary completion
- Jul 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of lorlatinib in solid tumor and lymphoma (5 arms), sponsored by Pfizer. Primary endpoints: Area Under Plasma Lorlatinib Concentration-Time Curve From Time 0 to Dosing Interval of 24 Hours and Observed Maximal Plasma Concentration. Started Jan 2020; status: terminated.
02
Drugs
lorlatinib
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03726333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03726333.